Working capital / assets moved 255 bp lower
Working capital / assets changed -255 basis points from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
24.80%→22.25%4 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →OSK financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Current assets increased 10.0%
Current assets changed +10.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$4.9B→$5.4B4 prior comparisons
Inventory / revenue moved 1117 bp lower
Inventory / revenue changed -1117 basis points from the comparable as-filed period.
91.42%→80.24%2 prior comparisons
Total assets increased 4.2%
Total assets changed +4.2% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$9.8B→$10.3B4 prior comparisons
Inventory decreased 7.2%
Inventory changed -7.2% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$2.5B→$2.3B4 prior comparisons
Free-cash-flow margin moved 707 bp lower
Free-cash-flow margin changed -707 basis points from the comparable as-filed period.
16.74%→9.67%2 prior comparisons
Operating cash-flow margin moved 693 bp lower
Operating cash-flow margin changed -693 basis points from the comparable as-filed period.
18.19%→11.26%2 prior comparisons
Current ratio decreased 12.8%
Current ratio changed -12.8% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
1.98→1.724 prior comparisons
Capital expenditure increased 16.2%
Capital expenditure changed +16.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$38.9M→$45.2M3 prior comparisons
Revenue increased 5.7%
Revenue changed +5.7% from the comparable as-filed period.
$2.7B→$2.8B2 prior comparisons
Capex / revenue moved 14 bp higher
Capex / revenue changed +14 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
1.45%→1.59%2 prior comparisons
Selling, general & administrative increased 16.7%
Selling, general & administrative changed +16.7% from the comparable as-filed period.
$196.2M→$228.9M2 prior comparisons
Research & development increased 7.1%
Research & development changed +7.1% from the comparable as-filed period.
$39.4M→$42.2M2 prior comparisons
Working capital decreased 6.5%
Working capital changed -6.5% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
$2.4B→$2.3B4 prior comparisons
Cost of revenue increased 8.3%
Cost of revenue changed +8.3% from the comparable as-filed period.
$2.2B→$2.4B2 prior comparisons
SBC / revenue moved 2 bp higher
SBC / revenue changed +2 basis points from the comparable as-filed period.
0.40%→0.42%2 prior comparisons
Gross profit decreased 6.4%
Gross profit changed -6.4% from the comparable as-filed period.
$470.5M→$440.3M2 prior comparisons
Stock-based compensation increased 11.2%
Stock-based compensation changed +11.2% from the comparable as-filed period.
$10.7M→$11.9M2 prior comparisons
Operating cash flow / net income decreased 7.3%
Operating cash flow / net income changed -7.3% from the comparable as-filed period.
2.49→2.312 prior comparisons
R&D / revenue moved 2 bp higher
R&D / revenue changed +2 basis points from the comparable as-filed period.
1.47%→1.49%2 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.